Please contact our sales team for your Consulting and Customization queries/concerns at [email protected].
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
- Innovative
- Generic
Segment by Application
- Oncology
- Glaucoma
- Hormonal Imbalance
- Respiratory Disorders
- Other
By Region
- North America
- - U.S.
- - Canada
- Europe
- - Germany
- - France
- - U.K.
- - Italy
- - Russia
- Asia-Pacific
- - China
- - Japan
- - South Korea
- - India
- - Australia
- - Taiwan
- - Indonesia
- - Thailand
- - Malaysia
- - Philippines
- - Vietnam
- Latin America
- - Mexico
- - Brazil
- - Argentina
- Middle East & Africa
- - Turkey
- - Saudi Arabia
- - UAE
By Company
- Pfizer (US)
- Novartis (Switzerland)
- Sanofi (France)
- Roche (Switzerland)
- Eli Lilly and Company (US)
- Merck (US)
- AbbVie (US)
- Boehringer Ingelheim (Germany)
- GlaxoSmithKline (UK)
- RAG-Stiftung (Germany)
- Bristol-Myers Squibb (US)
- Teva (Israel)
- Mylan (US)
- AstraZeneca (UK)
- Lonza (Swiss)
- Ash Stevens (US)
- AMRI (US)
Table of Contents
1 High Potency APIs (HPAPI) Market Overview
1.1 Product Overview and Scope of High Potency APIs (HPAPI)
1.2 High Potency APIs (HPAPI) Segment by Type
1.2.1 Global High Potency APIs (HPAPI) Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Innovative
1.2.3 Generic
1.3 High Potency APIs (HPAPI) Segment by Application
1.3.1 Global High Potency APIs (HPAPI) Sales Comparison by Application: (2022-2028)
1.3.2 Oncology
1.3.3 Glaucoma
1.3.4 Hormonal Imbalance
1.3.5 Respiratory Disorders
1.3.6 Other
1.4 Global High Potency APIs (HPAPI) Market Size Estimates and Forecasts
1.4.1 Global High Potency APIs (HPAPI) Revenue 2017-2028
1.4.2 Global High Potency APIs (HPAPI) Sales 2017-2028
1.4.3 High Potency APIs (HPAPI) Market Size by Region: 2017 Versus 2021 Versus 2028
2 High Potency APIs (HPAPI) Market Competition by Manufacturers
2.1 Global High Potency APIs (HPAPI) Sales Market Share by Manufacturers (2017-2022)
2.2 Global High Potency APIs (HPAPI) Revenue Market Share by Manufacturers (2017-2022)
2.3 Global High Potency APIs (HPAPI) Average Price by Manufacturers (2017-2022)
2.4 Manufacturers High Potency APIs (HPAPI) Manufacturing Sites, Area Served, Product Type
2.5 High Potency APIs (HPAPI) Market Competitive Situation and Trends
2.5.1 High Potency APIs (HPAPI) Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest High Potency APIs (HPAPI) Players Market Share by Revenue
2.5.3 Global High Potency APIs (HPAPI) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 High Potency APIs (HPAPI) Retrospective Market Scenario by Region
3.1 Global High Potency APIs (HPAPI) Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global High Potency APIs (HPAPI) Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America High Potency APIs (HPAPI) Market Facts & Figures by Country
3.3.1 North America High Potency APIs (HPAPI) Sales by Country
3.3.2 North America High Potency APIs (HPAPI) Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe High Potency APIs (HPAPI) Market Facts & Figures by Country
3.4.1 Europe High Potency APIs (HPAPI) Sales by Country
3.4.2 Europe High Potency APIs (HPAPI) Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific High Potency APIs (HPAPI) Market Facts & Figures by Region
3.5.1 Asia Pacific High Potency APIs (HPAPI) Sales by Region
3.5.2 Asia Pacific High Potency APIs (HPAPI) Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America High Potency APIs (HPAPI) Market Facts & Figures by Country
3.6.1 Latin America High Potency APIs (HPAPI) Sales by Country
3.6.2 Latin America High Potency APIs (HPAPI) Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa High Potency APIs (HPAPI) Market Facts & Figures by Country
3.7.1 Middle East and Africa High Potency APIs (HPAPI) Sales by Country
3.7.2 Middle East and Africa High Potency APIs (HPAPI) Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global High Potency APIs (HPAPI) Historic Market Analysis by Type
4.1 Global High Potency APIs (HPAPI) Sales Market Share by Type (2017-2022)
4.2 Global High Potency APIs (HPAPI) Revenue Market Share by Type (2017-2022)
4.3 Global High Potency APIs (HPAPI) Price by Type (2017-2022)
5 Global High Potency APIs (HPAPI) Historic Market Analysis by Application
5.1 Global High Potency APIs (HPAPI) Sales Market Share by Application (2017-2022)
5.2 Global High Potency APIs (HPAPI) Revenue Market Share by Application (2017-2022)
5.3 Global High Potency APIs (HPAPI) Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Pfizer (US)
6.1.1 Pfizer (US) Corporation Information
6.1.2 Pfizer (US) Description and Business Overview
6.1.3 Pfizer (US) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Pfizer (US) High Potency APIs (HPAPI) Product Portfolio
6.1.5 Pfizer (US) Recent Developments/Updates
6.2 Novartis (Switzerland)
6.2.1 Novartis (Switzerland) Corporation Information
6.2.2 Novartis (Switzerland) Description and Business Overview
6.2.3 Novartis (Switzerland) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Novartis (Switzerland) High Potency APIs (HPAPI) Product Portfolio
6.2.5 Novartis (Switzerland) Recent Developments/Updates
6.3 Sanofi (France)
6.3.1 Sanofi (France) Corporation Information
6.3.2 Sanofi (France) Description and Business Overview
6.3.3 Sanofi (France) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Sanofi (France) High Potency APIs (HPAPI) Product Portfolio
6.3.5 Sanofi (France) Recent Developments/Updates
6.4 Roche (Switzerland)
6.4.1 Roche (Switzerland) Corporation Information
6.4.2 Roche (Switzerland) Description and Business Overview
6.4.3 Roche (Switzerland) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Roche (Switzerland) High Potency APIs (HPAPI) Product Portfolio
6.4.5 Roche (Switzerland) Recent Developments/Updates
6.5 Eli Lilly and Company (US)
6.5.1 Eli Lilly and Company (US) Corporation Information
6.5.2 Eli Lilly and Company (US) Description and Business Overview
6.5.3 Eli Lilly and Company (US) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Eli Lilly and Company (US) High Potency APIs (HPAPI) Product Portfolio
6.5.5 Eli Lilly and Company (US) Recent Developments/Updates
6.6 Merck (US)
6.6.1 Merck (US) Corporation Information
6.6.2 Merck (US) Description and Business Overview
6.6.3 Merck (US) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Merck (US) High Potency APIs (HPAPI) Product Portfolio
6.6.5 Merck (US) Recent Developments/Updates
6.7 AbbVie (US)
6.6.1 AbbVie (US) Corporation Information
6.6.2 AbbVie (US) Description and Business Overview
6.6.3 AbbVie (US) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2017-2022)
6.4.4 AbbVie (US) High Potency APIs (HPAPI) Product Portfolio
6.7.5 AbbVie (US) Recent Developments/Updates
6.8 Boehringer Ingelheim (Germany)
6.8.1 Boehringer Ingelheim (Germany) Corporation Information
6.8.2 Boehringer Ingelheim (Germany) Description and Business Overview
6.8.3 Boehringer Ingelheim (Germany) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Boehringer Ingelheim (Germany) High Potency APIs (HPAPI) Product Portfolio
6.8.5 Boehringer Ingelheim (Germany) Recent Developments/Updates
6.9 GlaxoSmithKline (UK)
6.9.1 GlaxoSmithKline (UK) Corporation Information
6.9.2 GlaxoSmithKline (UK) Description and Business Overview
6.9.3 GlaxoSmithKline (UK) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2017-2022)
6.9.4 GlaxoSmithKline (UK) High Potency APIs (HPAPI) Product Portfolio
6.9.5 GlaxoSmithKline (UK) Recent Developments/Updates
6.10 RAG-Stiftung (Germany)
6.10.1 RAG-Stiftung (Germany) Corporation Information
6.10.2 RAG-Stiftung (Germany) Description and Business Overview
6.10.3 RAG-Stiftung (Germany) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2017-2022)
6.10.4 RAG-Stiftung (Germany) High Potency APIs (HPAPI) Product Portfolio
6.10.5 RAG-Stiftung (Germany) Recent Developments/Updates
6.11 Bristol-Myers Squibb (US)
6.11.1 Bristol-Myers Squibb (US) Corporation Information
6.11.2 Bristol-Myers Squibb (US) High Potency APIs (HPAPI) Description and Business Overview
6.11.3 Bristol-Myers Squibb (US) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Bristol-Myers Squibb (US) High Potency APIs (HPAPI) Product Portfolio
6.11.5 Bristol-Myers Squibb (US) Recent Developments/Updates
6.12 Teva (Israel)
6.12.1 Teva (Israel) Corporation Information
6.12.2 Teva (Israel) High Potency APIs (HPAPI) Description and Business Overview
6.12.3 Teva (Israel) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Teva (Israel) High Potency APIs (HPAPI) Product Portfolio
6.12.5 Teva (Israel) Recent Developments/Updates
6.13 Mylan (US)
6.13.1 Mylan (US) Corporation Information
6.13.2 Mylan (US) High Potency APIs (HPAPI) Description and Business Overview
6.13.3 Mylan (US) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Mylan (US) High Potency APIs (HPAPI) Product Portfolio
6.13.5 Mylan (US) Recent Developments/Updates
6.14 AstraZeneca (UK)
6.14.1 AstraZeneca (UK) Corporation Information
6.14.2 AstraZeneca (UK) High Potency APIs (HPAPI) Description and Business Overview
6.14.3 AstraZeneca (UK) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2017-2022)
6.14.4 AstraZeneca (UK) High Potency APIs (HPAPI) Product Portfolio
6.14.5 AstraZeneca (UK) Recent Developments/Updates
6.15 Lonza (Swiss?
6.15.1 Lonza (Swiss? Corporation Information
6.15.2 Lonza (Swiss? High Potency APIs (HPAPI) Description and Business Overview
6.15.3 Lonza (Swiss? High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2017-2022)
6.15.4 Lonza (Swiss? High Potency APIs (HPAPI) Product Portfolio
6.15.5 Lonza (Swiss? Recent Developments/Updates
6.16 Ash Stevens (US)
6.16.1 Ash Stevens (US) Corporation Information
6.16.2 Ash Stevens (US) High Potency APIs (HPAPI) Description and Business Overview
6.16.3 Ash Stevens (US) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2017-2022)
6.16.4 Ash Stevens (US) High Potency APIs (HPAPI) Product Portfolio
6.16.5 Ash Stevens (US) Recent Developments/Updates
6.17 AMRI (US)
6.17.1 AMRI (US) Corporation Information
6.17.2 AMRI (US) High Potency APIs (HPAPI) Description and Business Overview
6.17.3 AMRI (US) High Potency APIs (HPAPI) Sales, Revenue and Gross Margin (2017-2022)
6.17.4 AMRI (US) High Potency APIs (HPAPI) Product Portfolio
6.17.5 AMRI (US) Recent Developments/Updates
7 High Potency APIs (HPAPI) Manufacturing Cost Analysis
7.1 High Potency APIs (HPAPI) Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of High Potency APIs (HPAPI)
7.4 High Potency APIs (HPAPI) Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 High Potency APIs (HPAPI) Distributors List
8.3 High Potency APIs (HPAPI) Customers
9 High Potency APIs (HPAPI) Market Dynamics
9.1 High Potency APIs (HPAPI) Industry Trends
9.2 High Potency APIs (HPAPI) Market Drivers
9.3 High Potency APIs (HPAPI) Market Challenges
9.4 High Potency APIs (HPAPI) Market Restraints
10 Global Market Forecast
10.1 High Potency APIs (HPAPI) Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of High Potency APIs (HPAPI) by Type (2023-2028)
10.1.2 Global Forecasted Revenue of High Potency APIs (HPAPI) by Type (2023-2028)
10.2 High Potency APIs (HPAPI) Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of High Potency APIs (HPAPI) by Application (2023-2028)
10.2.2 Global Forecasted Revenue of High Potency APIs (HPAPI) by Application (2023-2028)
10.3 High Potency APIs (HPAPI) Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of High Potency APIs (HPAPI) by Region (2023-2028)
10.3.2 Global Forecasted Revenue of High Potency APIs (HPAPI) by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global High Potency APIs (HPAPI) Sales Growth Rate Comparison by Type (2022-2028) & (KG) & (US$ Million)
Table 2. Global High Potency APIs (HPAPI) Sales Growth Rate Comparison by Application (2022-2028) & (KG) & (US$ Million)
Table 3. Global High Potency APIs (HPAPI) Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global High Potency APIs (HPAPI) Market Competitive Situation by Manufacturers in 2021
Table 5. Global High Potency APIs (HPAPI) Sales (KG) of Key Manufacturers (2017-2022)
Table 6. Global High Potency APIs (HPAPI) Sales Market Share by Manufacturers (2017-2022)
Table 7. Global High Potency APIs (HPAPI) Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global High Potency APIs (HPAPI) Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market High Potency APIs (HPAPI) Average Price (USD/KG) of Key Manufacturers (2017-2022)
Table 10. Manufacturers High Potency APIs (HPAPI) Manufacturing Sites and Area Served
Table 11. Manufacturers High Potency APIs (HPAPI) Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global High Potency APIs (HPAPI) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in High Potency APIs (HPAPI) as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global High Potency APIs (HPAPI) Sales by Region (2017-2022) & (KG)
Table 16. Global High Potency APIs (HPAPI) Sales Market Share by Region (2017-2022)
Table 17. Global High Potency APIs (HPAPI) Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global High Potency APIs (HPAPI) Revenue Market Share by Region (2017-2022)
Table 19. North America High Potency APIs (HPAPI) Sales by Country (2017-2022) & (KG)
Table 20. North America High Potency APIs (HPAPI) Sales Market Share by Country (2017-2022)
Table 21. North America High Potency APIs (HPAPI) Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America High Potency APIs (HPAPI) Revenue Market Share by Country (2017-2022)
Table 23. Europe High Potency APIs (HPAPI) Sales by Country (2017-2022) & (KG)
Table 24. Europe High Potency APIs (HPAPI) Sales Market Share by Country (2017-2022)
Table 25. Europe High Potency APIs (HPAPI) Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe High Potency APIs (HPAPI) Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific High Potency APIs (HPAPI) Sales by Region (2017-2022) & (KG)
Table 28. Asia Pacific High Potency APIs (HPAPI) Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific High Potency APIs (HPAPI) Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific High Potency APIs (HPAPI) Revenue Market Share by Region (2017-2022)
Table 31. Latin America High Potency APIs (HPAPI) Sales by Country (2017-2022) & (KG)
Table 32. Latin America High Potency APIs (HPAPI) Sales Market Share by Country (2017-2022)
Table 33. Latin America High Potency APIs (HPAPI) Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America High Potency APIs (HPAPI) Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa High Potency APIs (HPAPI) Sales by Country (2017-2022) & (KG)
Table 36. Middle East and Africa High Potency APIs (HPAPI) Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa High Potency APIs (HPAPI) Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa High Potency APIs (HPAPI) Revenue Market Share by Country (2017-2022)
Table 39. Global High Potency APIs (HPAPI) Sales by Type (2017-2022) & (KG)
Table 40. Global High Potency APIs (HPAPI) Sales Market Share by Type (2017-2022)
Table 41. Global High Potency APIs (HPAPI) Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global High Potency APIs (HPAPI) Revenue Share by Type (2017-2022)
Table 43. Global High Potency APIs (HPAPI) Price by Type (2017-2022) & (USD/KG)
Table 44. Global High Potency APIs (HPAPI) Sales (KG) by Application (2017-2022)
Table 45. Global High Potency APIs (HPAPI) Sales Market Share by Application (2017-2022)
Table 46. Global High Potency APIs (HPAPI) Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global High Potency APIs (HPAPI) Revenue Share by Application (2017-2022)
Table 48. Global High Potency APIs (HPAPI) Price by Application (2017-2022) & (USD/KG)
Table 49. Pfizer (US) Corporation Information
Table 50. Pfizer (US) Description and Business Overview
Table 51. Pfizer (US) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 52. Pfizer (US) High Potency APIs (HPAPI) Product
Table 53. Pfizer (US) Recent Developments/Updates
Table 54. Novartis (Switzerland) Corporation Information
Table 55. Novartis (Switzerland) Description and Business Overview
Table 56. Novartis (Switzerland) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 57. Novartis (Switzerland) High Potency APIs (HPAPI) Product
Table 58. Novartis (Switzerland) Recent Developments/Updates
Table 59. Sanofi (France) Corporation Information
Table 60. Sanofi (France) Description and Business Overview
Table 61. Sanofi (France) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 62. Sanofi (France) High Potency APIs (HPAPI) Product
Table 63. Sanofi (France) Recent Developments/Updates
Table 64. Roche (Switzerland) Corporation Information
Table 65. Roche (Switzerland) Description and Business Overview
Table 66. Roche (Switzerland) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 67. Roche (Switzerland) High Potency APIs (HPAPI) Product
Table 68. Roche (Switzerland) Recent Developments/Updates
Table 69. Eli Lilly and Company (US) Corporation Information
Table 70. Eli Lilly and Company (US) Description and Business Overview
Table 71. Eli Lilly and Company (US) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 72. Eli Lilly and Company (US) High Potency APIs (HPAPI) Product
Table 73. Eli Lilly and Company (US) Recent Developments/Updates
Table 74. Merck (US) Corporation Information
Table 75. Merck (US) Description and Business Overview
Table 76. Merck (US) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 77. Merck (US) High Potency APIs (HPAPI) Product
Table 78. Merck (US) Recent Developments/Updates
Table 79. AbbVie (US) Corporation Information
Table 80. AbbVie (US) Description and Business Overview
Table 81. AbbVie (US) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 82. AbbVie (US) High Potency APIs (HPAPI) Product
Table 83. AbbVie (US) Recent Developments/Updates
Table 84. Boehringer Ingelheim (Germany) Corporation Information
Table 85. Boehringer Ingelheim (Germany) Description and Business Overview
Table 86. Boehringer Ingelheim (Germany) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 87. Boehringer Ingelheim (Germany) High Potency APIs (HPAPI) Product
Table 88. Boehringer Ingelheim (Germany) Recent Developments/Updates
Table 89. GlaxoSmithKline (UK) Corporation Information
Table 90. GlaxoSmithKline (UK) Description and Business Overview
Table 91. GlaxoSmithKline (UK) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 92. GlaxoSmithKline (UK) High Potency APIs (HPAPI) Product
Table 93. GlaxoSmithKline (UK) Recent Developments/Updates
Table 94. RAG-Stiftung (Germany) Corporation Information
Table 95. RAG-Stiftung (Germany) Description and Business Overview
Table 96. RAG-Stiftung (Germany) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 97. RAG-Stiftung (Germany) High Potency APIs (HPAPI) Product
Table 98. RAG-Stiftung (Germany) Recent Developments/Updates
Table 99. Bristol-Myers Squibb (US) Corporation Information
Table 100. Bristol-Myers Squibb (US) Description and Business Overview
Table 101. Bristol-Myers Squibb (US) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 102. Bristol-Myers Squibb (US) High Potency APIs (HPAPI) Product
Table 103. Bristol-Myers Squibb (US) Recent Developments/Updates
Table 104. Teva (Israel) Corporation Information
Table 105. Teva (Israel) Description and Business Overview
Table 106. Teva (Israel) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 107. Teva (Israel) High Potency APIs (HPAPI) Product
Table 108. Teva (Israel) Recent Developments/Updates
Table 109. Mylan (US) Corporation Information
Table 110. Mylan (US) Description and Business Overview
Table 111. Mylan (US) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 112. Mylan (US) High Potency APIs (HPAPI) Product
Table 113. Mylan (US) Recent Developments/Updates
Table 114. AstraZeneca (UK) Corporation Information
Table 115. AstraZeneca (UK) Description and Business Overview
Table 116. AstraZeneca (UK) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 117. AstraZeneca (UK) High Potency APIs (HPAPI) Product
Table 118. AstraZeneca (UK) Recent Developments/Updates
Table 119. Lonza (Swiss? Corporation Information
Table 120. Lonza (Swiss? Description and Business Overview
Table 121. Lonza (Swiss? High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 122. Lonza (Swiss? High Potency APIs (HPAPI) Product
Table 123. Lonza (Swiss? Recent Developments/Updates
Table 124. Ash Stevens (US) Corporation Information
Table 125. Ash Stevens (US) Description and Business Overview
Table 126. Ash Stevens (US) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 127. Ash Stevens (US) High Potency APIs (HPAPI) Product
Table 128. Ash Stevens (US) Recent Developments/Updates
Table 129. AMRI (US) Corporation Information
Table 130. AMRI (US) Description and Business Overview
Table 131. AMRI (US) High Potency APIs (HPAPI) Sales (KG), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2017-2022)
Table 132. AMRI (US) High Potency APIs (HPAPI) Product
Table 133. AMRI (US) Recent Developments/Updates
Table 134. Production Base and Market Concentration Rate of Raw Material
Table 135. Key Suppliers of Raw Materials
Table 136. High Potency APIs (HPAPI) Distributors List
Table 137. High Potency APIs (HPAPI) Customers List
Table 138. High Potency APIs (HPAPI) Market Trends
Table 139. High Potency APIs (HPAPI) Market Drivers
Table 140. High Potency APIs (HPAPI) Market Challenges
Table 141. High Potency APIs (HPAPI) Market Restraints
Table 142. Global High Potency APIs (HPAPI) Sales Forecast by Type (2023-2028) & (KG)
Table 143. Global High Potency APIs (HPAPI) Sales Market Share Forecast by Type (2023-2028)
Table 144. Global High Potency APIs (HPAPI) Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 145. Global High Potency APIs (HPAPI) Revenue Market Share Forecast by Type (2023-2028)
Table 146. Global High Potency APIs (HPAPI) Sales Forecast by Application (2023-2028) & (KG)
Table 147. Global High Potency APIs (HPAPI) Sales Market Share Forecast by Application (2023-2028)
Table 148. Global High Potency APIs (HPAPI) Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 149. Global High Potency APIs (HPAPI) Revenue Market Share Forecast by Application (2023-2028)
Table 150. Global High Potency APIs (HPAPI) Sales Forecast by Region (2023-2028) & (KG)
Table 151. Global High Potency APIs (HPAPI) Sales Market Share Forecast by Region (2023-2028)
Table 152. Global High Potency APIs (HPAPI) Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 153. Global High Potency APIs (HPAPI) Revenue Market Share Forecast by Region (2023-2028)
Table 154. Research Programs/Design for This Report
Table 155. Key Data Information from Secondary Sources
Table 156. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of High Potency APIs (HPAPI)
Figure 2. Global High Potency APIs (HPAPI) Market Share by Type in 2021 & 2028
Figure 3. Innovative Product Picture
Figure 4. Generic Product Picture
Figure 5. Global High Potency APIs (HPAPI) Market Share by Application in 2021 & 2028
Figure 6. Oncology
Figure 7. Glaucoma
Figure 8. Hormonal Imbalance
Figure 9. Respiratory Disorders
Figure 10. Other
Figure 11. Global High Potency APIs (HPAPI) Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 12. Global High Potency APIs (HPAPI) Market Size (2017-2028) & (US$ Million)
Figure 13. Global High Potency APIs (HPAPI) Sales (2017-2028) & (KG)
Figure 14. High Potency APIs (HPAPI) Sales Share by Manufacturers in 2021
Figure 15. Global High Potency APIs (HPAPI) Revenue Share by Manufacturers in 2021
Figure 16. The Global 5 and 10 Largest High Potency APIs (HPAPI) Players: Market Share by Revenue in 2021
Figure 17. High Potency APIs (HPAPI) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 18. Global High Potency APIs (HPAPI) Sales Market Share by Region (2017-2022)
Figure 19. Global High Potency APIs (HPAPI) Sales Market Share by Region in 2021
Figure 20. Global High Potency APIs (HPAPI) Revenue Market Share by Region (2017-2022)
Figure 21. Global High Potency APIs (HPAPI) Revenue Market Share by Region in 2021
Figure 22. U.S. High Potency APIs (HPAPI) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. Canada High Potency APIs (HPAPI) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. Germany High Potency APIs (HPAPI) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. France High Potency APIs (HPAPI) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. U.K. High Potency APIs (HPAPI) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. Italy High Potency APIs (HPAPI) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. Russia High Potency APIs (HPAPI) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. China High Potency APIs (HPAPI) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. Japan High Potency APIs (HPAPI) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. South Korea High Potency APIs (HPAPI) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. India High Potency APIs (HPAPI) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. Australia High Potency APIs (HPAPI) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Taiwan High Potency APIs (HPAPI) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Indonesia High Potency APIs (HPAPI) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Thailand High Potency APIs (HPAPI) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Malaysia High Potency APIs (HPAPI) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Philippines High Potency APIs (HPAPI) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Vietnam High Potency APIs (HPAPI) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Mexico High Potency APIs (HPAPI) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Brazil High Potency APIs (HPAPI) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Argentina High Potency APIs (HPAPI) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. Turkey High Potency APIs (HPAPI) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 44. Saudi Arabia High Potency APIs (HPAPI) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 45. UAE High Potency APIs (HPAPI) Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 46. Sales Market Share of High Potency APIs (HPAPI) by Type (2017-2022)
Figure 47. Manufacturing Cost Structure of High Potency APIs (HPAPI)
Figure 48. Manufacturing Process Analysis of High Potency APIs (HPAPI)
Figure 49. High Potency APIs (HPAPI) Industrial Chain Analysis
Figure 50. Channels of Distribution
Figure 51. Distributors Profiles
Figure 52. Bottom-up and Top-down Approaches for This Report
Figure 53. Data Triangulation
Figure 54. Key Executives Interviewed
|
Global High Potency APIs (HPAPI) Market Research Report 2023, Forecast to 2028
Highly potent APIs (HPAPIs) are a rapidly growing segment of the pharmaceutical industry. More than 1,000 small molecule highly potent drug products are currently in development, and market estimates project close to 10% annual growth in this space.... |
|
Global High Potency APIs (HPAPI) Professional Survey Report 2023, Forecast to 2028
Highly potent APIs (HPAPIs) are a rapidly growing segment of the pharmaceutical industry. More than 1,000 small molecule highly potent drug products are currently in development, and market estimates project close to 10% annual growth in this space.... |
|
Global High Potency APIs (HPAPI) Market Research Report 2023
HPAPI is a very effective pharmacological active ingredient.Their effects are highly specific, providing significant efficiencies even at low daily therapeutic doses. Highlights The global High Potency APIs (HPAPI) market was valued at ... |
|
Global High Potency APIs (HPAPI) Market Insights: Impact of COVID-19 and Future Expectations to 2028
The High Potency APIs (HPAPI) market revenue was XX Million USD in 2022, and will reach XX Million USD in 2028, with a CAGR of XX% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of t... |
|
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region - Global forecast to 2027
The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and othe... |
|
Global High Potency APIs (HPAPI) Market Research Report 2021 - Impact of COVID-19 on the Market
The High Potency APIs (HPAPI) market revenue was xx Million USD in 2016, grew to xx Million USD in 2021, and will reach xx Million USD in 2026, with a CAGR of xx during 2021-2026. Considering the influence of COVID-19 on the gl... |
|
Global High Potency APIs (HPAPI) Market Insights and Forecast to 2028
High Potency APIs (HPAPI) market is segmented by Type and by Application. Players, stakeholders, and other participants in the global High Potency APIs (HPAPI) market will be able to gain the upper hand as they use the report as a powerful resource. ... |
|
Global High Potency APIs (HPAPI) Professional Survey Report 2022, Forecast to 2027
Highly potent APIs (HPAPIs) are a rapidly growing segment of the pharmaceutical industry. More than 1,000 small molecule highly potent drug products are currently in development, and market estimates project close to 10% annual growth in this space.... |
|
Global High Potency APIs (HPAPI) Market Research Report 2022, Forecast to 2027
Highly potent APIs (HPAPIs) are a rapidly growing segment of the pharmaceutical industry. More than 1,000 small molecule highly potent drug products are currently in development, and market estimates project close to 10% annual growth in this space.... |
|
2022-2029 Global High Potency APIs (HPAPI) Professional Market Research Report, Analysis from Perspective of Segmentation (Competitor Landscape, Type, Application, and Geography)
The High Potency APIs (HPAPI) market has witnessed growth from USD XX million to USD XX million from 2017 to 2022. With the CAGR of X.X%, this market is estimated to reach USD XX million in 2029. The report focuses on the High Potency ... |
